ELOXATIN 50 MG — DIN 02296268
OXALIPLATIN : 50 MG · SANOFI-AVENTIS CANADA INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ELOXATIN?
ELOXATIN 50 MG contains OXALIPLATIN : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02296268, held by SANOFI-AVENTIS CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 03-Aug-2016. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ELOXATIN used for?
Adjuvant treatment of stage III colon cancer after resection; treatment of metastatic colorectal cancer. Used in combination with 5-fluorouracil/leucovorin (5-FU/LV).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Oxaliplatin cost around the world?
Oxaliplatin is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 18 | 26 | SAR███.██ |
| South Africa | single exit price | 22 | 22 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 5 | 11 | CZK███.██ |
| United Arab Emirates | public | 6 | 8 | AED███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Romania | max producer price | 2 | 6 | RON███.██ |
| Australia | ex-manufacturer | 2 | 4 | AUD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 2 | USD███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
90 pack listings across 67 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Oxaliplatin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Oxaliplatin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Oxaliplatin, across 22 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 2 | 1 | OXALIPLATIN INJECTION, TEVA-OXALIPLATIN INJECTION | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 1 | 1 | OXALIPLATIN INJECTION, USP | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | OXALIPLATIN INJECTION, USP | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | OXALIPLATIN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | OXALIPLATIN INJECTION | Sourceable in Canada |
| ACTAVIS PHARMA COMPANY | 3 | 0 | ACT OXALIPLATIN | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 3 | 0 | OXALIPLATIN FOR INJECTION, OXALIPLATIN INJECTION | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 3 | 0 | ELOXATIN | No marketed DIN |
| AURO PHARMA INC | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| EUGIA PHARMA INC. | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| GENERIC MEDICAL PARTNERS INC | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-OXALIPLATIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Lyophilized powder: 50 mg and 100 mg vials. Aqueous solution: 50 mg/10 mL, 100 mg/20 mL, and 200 mg/40 mL vials. |
| Storage | Store at 15-30°C. Do not freeze. Protect from light. (Note: Specific storage for reconstituted solution varies). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Oxaliplatin |
|---|---|
| ATC code | L01XA03 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02296268 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2296268 |
| Brand name | ELOXATIN |
| Generic / active ingredient | OXALIPLATIN : 50 MG |
| Market authorization holder | SANOFI-AVENTIS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L01XA03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XA |
| Current status | CANCELLED POST MARKET |
| Status date | 03-Aug-2016 |
| Original market date | 2008-06-27 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered as 2-hour IV infusion. In combination with 5-FU/LV, recommended dose is 85 mg/m2 every 2 weeks. Dosage adjustments required for neurological symptoms or hematologic toxicity.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
History of allergy to oxaliplatin or platinum compounds; breast-feeding; pregnancy; severe renal impairment (creatinine clearance < 30 mL/min).
Warnings and precautions
Serious risks: Anaphylaxis, QT prolongation, interstitial lung disease, hepatotoxicity, rhabdomyolysis, myelosuppression, and severe sensory/motor neuropathy. Avoid cold exposure.
Is Oxaliplatin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by DR REDDY'S LABORATORIES LTD, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 22 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OXALIPLATIN | 5 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02444763 |
| OXALIPLATIN INJECTION | 5 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02436957 |
| OXALIPLATIN INJECTION | 5 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02435071 |
| OXALIPLATIN INJECTION, USP | 5 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02457423 |
| OXALIPLATIN INJECTION, USP | 5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02458403 |
| ACT OXALIPLATIN | 100 MG | POWDER FOR SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02430533 |
| ACT OXALIPLATIN | 50 MG | POWDER FOR SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02430525 |
| ACT OXALIPLATIN | 5 MG | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | 02432617 |
| ELOXATIN | 100 MG | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02296276 |
| ELOXATIN | 5 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02296284 |
2 · Same class — other molecules in ATC L01XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Oxaliplatin | ACT OXALIPLATIN · ELOXATIN · OXALIPLATIN · OXALIPLATIN FOR INJECTION · +6 more | 22 | 5 | Yes |
| Cisplatin | CISPLATIN INJ 0.5MG/ML · CISPLATIN INJ 1MG/ML · CISPLATIN INJECTION · CISPLATIN INJECTION BP · +4 more | 13 | 4 | Yes |
| Carboplatin | CARBOPLATIN INJECTION · CARBOPLATIN INJECTION BP · CARBOPLATIN INJECTION LIQ 10MG/ML · CARBOPLATIN INJECTION, BP · +2 more | 10 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XX | Aflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · +13 more | 48 | 23 |
| L01XG | Bortezomib · Carfilzomib · Ixazomib | 30 | 18 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · +2 more | 8 | 5 |
| L01XJ | Glasdegib · Sonidegib · Vismodegib | 4 | 4 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XM | Enasidenib · Vorasidenib | 4 | 2 |
| L01XF | Tretinoin | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ELOXATIN called?
The same molecule, Oxaliplatin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Oxaliplatin Accord | Latin | Australia, Czechia |
| OXALIPLATIN KALCEKS | Latin | Czechia |
| Xaliptine | Latin | Saudi Arabia |
| OXALIPLATIN | Latin | Lebanon |
| OXALIPLATIN BAXTER | Latin | Australia |
| OXALIPLATIN KABI | Latin | Czechia |
| OXALIPLATIN TEVA | Latin | Czechia |
| OXALIPLATIN AGMED | Latin | Czechia |
| OXALIPLATIN EBEWE | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.